compass_positive_tagline-01.png
Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression
January 19, 2022 07:00 ET | COMPASS Pathways
London, UK and New York, US, 19 January 2022  COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
compass_positive_tagline-01.png
COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology
January 04, 2022 07:00 ET | COMPASS Pathways
Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist support London, UK – 4 January...
compass_positive_tagline-01.png
COMPASS Pathways announces changes in Executive Team
December 16, 2021 07:40 ET | COMPASS Pathways
Matthew Owens appointed General Counsel and Chief Legal Officer; Lars Wilde, Chief Business Officer and Co-founder, to move into senior advisory role London, UK – 16 December...
compass_positive_tagline-01.png
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
December 13, 2021 07:00 ET | COMPASS Pathways
Patients taking COMP360 psilocybin with concomitant SSRIs showed comparable treatment outcomes to patients withdrawn from their SSRI therapy in COMPASS’s phase IIb trialAll patients tolerated COMP360...
compass_positive_tagline-01.png
Michael Falvey joins COMPASS Pathways as Chief Financial Officer
December 03, 2021 07:00 ET | COMPASS Pathways
London, UK - 3 December 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
compass_positive_tagline-01.png
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
December 01, 2021 07:00 ET | COMPASS Pathways
- Positive topline results validated by additional analyses - Patient improvements beyond reduction of depression symptoms - Further insights into timing and circumstance of adverse...
compass_positive_tagline-01.png
COMPASS Pathways granted fifth US patent for crystalline psilocybin
November 23, 2021 07:00 ET | COMPASS Pathways
London, UK - 23 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
November 09, 2021 07:00 ET | COMPASS Pathways
Largest randomised, controlled, double-blind psilocybin therapy study ever completedshows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological...
compass_positive_tagline-01.png
COMPASS Pathways is granted new US patent for crystalline psilocybin
October 19, 2021 07:00 ET | COMPASS Pathways
London, UK – 19 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
compass_positive_tagline-01.png
Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds
September 10, 2021 07:00 ET | COMPASS Pathfinder Ltd.
      COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has engaged Hamilton Morris,...